Please amend the following claims under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

- 2. (Four times Amended) Purified FADD protein comprising the amino acid sequence shown in SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions produced by contacting a sample suspected of containing the FADD protein or polypeptide with a protein or polypeptide comprising the cytoplasmic domain of Fas under conditions suitable for the Fas-containing protein or polypeptide to bind the FADD protein or polypeptide to form a complex, and isolating any Fas-FADD complex formed, wherein the purified FADD protein has an apparent molecular weight of about 23.3 kDa as determined by an SDS polyacrylamide gel under reducing conditions.
- 3. (Four times Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 24 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.
- 37. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 41 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of the Fas receptor.
- 38. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 111 to amino acid 180 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of the Fas receptor.
- 39. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 35 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

Page 2

(Thrice Amended) A polypeptide fragment of claim 5, comprising amino acid 1 to amino 40.

acid 117 of SEQ ID NO:2, or an analog thereof having conservative amino acid substitutions and

the analog induces apoptosis in a suitable cell.

41. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino

acid 41 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid

substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

42. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino

acid 61 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid

substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

43. (Thrice Amended) A polypeptide fragment of the protein of claim 1, comprising amino

acid 80 to amino acid 208 of SEQ ID NO:2, or an analog thereof having conservative amino acid

substitutions and the analog binds to the cytoplasmic domain of a Fas receptor.

45. (Thrice Amended) A FADD mutein [protein] comprising the amino acid sequence shown

in SEQ ID NO:2 and having asparagine at amino acid 121, or an analog thereof having

conservative amino acid substitutions at amino acids 1 to 120 and 122 to 208, and the mutein or

analog induces apoptosis in a suitable cell.

57. (Amended) A method for screening for an agent of claim 29 or 30, further comprising

the step of analyzing the results of step b) to determine how the agent modulates apoptosis [the

cellular function regulated by the Fas receptor pathway].

(Amended) A method for screening for an agent useful to modulate a cellular function 58.

regulated by FADD, the method comprising the steps of:

Page 3

Serial No. 08/443,982

Docket No. 128019107020